HLA-G targeting exosomes (SOB100) is the only engineered exosomes specifically designed for HLA-G targeting in the world. SOB100 incorporates a nanobody-based anti-HLA-G antibody and can be loaded with various small molecule or nucleic acid drugs. This innovative platform offers a promising approach to treating solid tumors with high HLA-G expression. The development of the GMP industrial-scale production process has been successfully completed, and Phase I clinical trials are anticipated to commence in 2025.

1. HLA-G targeted exosome leading in the world: SOB100 targets to any HLA-G expressing cells.
2. Multi-functional drug delivery platform: SOB100 with the ability to be loaded indication specific drug.
3. Nanobody with high affinity to the target: With unique sequence, exposed CDR3 region of SOB100 is stable and with high affinity to the HLA-G.
4. Broad-Spectrum Anticancer Efficacy: With targeting HLA-G, SOB100 is potentially a cargo to deliver drugs for the treatment of breast cancer, ovarian cancer, brain cancer (GBM), pancreatic cancer lung cancer, and other solid tumors.